By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences and the Buck Institute for Research on Aging announced today a collaboration to develop mass spectrometry-based tests aimed at improving response to breast cancer therapies.

Under the terms of the deal, Proteome Sciences will support the development of mass spec assays that measure changes in estrogen receptor alpha, a biomarker associated with response to anti-estrogen therapies for breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.